Ocugen, Inc.

Ocugen, Inc.

0.77
USD
-0.05
(-6.62%)
-0.20EPS
349.49MMarket Cap
Mar 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.04
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.02
0.01
0.01
0.01
Basic EPS, GAAP
-120.93
-891.47
-145.22
-58.34
-59.55
-14.05
-1.46
-0.31
-0.3
-0.4
-0.26
-0.2
-0.23
-0.2
Free Cash Flow per Basic Share
-74.72
-831.47
-145.03
-109.65
-61.66
-29.32
-1.22
-0.13
-0.25
-0.3
-0.3
-0.17
-0.19
-0.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-419.91
254.98
127.46
39.42
-27.51
-0.44
0.21
0.12
0.48
0.33
0.16
0.1
-0.04
-0.05
Tangible Book Value per Share
-423.08
252.58
126.56
39.42
-27.51
-0.44
0.21
0.12
0.48
0.33
0.16
0.1
-0.04
-0.05
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
14
112
195
215
244
271
300
329
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
6
4
4
5
Operating Margin (%)
-209,812.5
- -
- -
- -
- -
- -
- -
-33,220.93
- -
-3,580.02
-1,085.67
-1,350.36
-1,425.7
-1,444.47
Depreciation Expense
1
1
2
2
2
- -
- -
- -
- -
- -
1
2
2
1
Net Income, GAAP
-26
-23
-32
-16
-26
-9
-20
-22
-58
-87
-63
-54
-68
-65
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-321,400
- -
- -
- -
- -
- -
- -
-50,748.84
- -
-3,488.91
-1,045.03
-1,333.02
-1,537.41
-1,367.61
Working Capital
5
52
25
27
4
14
11
22
96
70
26
40
1
-27
LT Debt
- -
1
1
- -
- -
- -
1
2
3
6
6
31
31
5
Total Equity
-76
54
28
14
-11
- -
11
22
96
74
41
30
-12
-18
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-77.72
-66.39
- -
- -
- -
-211.05
-99.46
-102.24
-110.14
-154.01
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
83
84
LT Borrowings
24
2
2
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
338
339
339
Market Capitalization
612
519
349

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
39
107
91
Cash, Cash Equivalents & STI
32
100
84
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
21
133
119
Payables & Accruals
5
7
12
ST Debt
6
83
84
Deferred Revenue
5
4
2

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-263.24%
21.73%
-141.06%
Free Cash Flow
18.94%
51.65%
25.53%
Net Income, GAAP
28.84%
40.01%
25.52%
Sales/Revenue/Turnover
- -
- -
8.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
4
2025
1
1
2
- -
4
2026
2
1
2
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.06
-0.04
-0.05
-0.2
2025
-0.05
-0.05
-0.06
-0.06
-0.23
2026
-0.06
-0.07
-0.01
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shankar Musunuri
Full Time Employees
116
Sector
Health technology
Industry
Pharmaceuticals: major
Address
263 Great Valley Parkway Malvern PA United States 19355
IPO Date
Dec 3, 2014
Website
ocugen.com
Business
Ocugen, Inc. is a clinical-stage biotechnology firm dedicated to advancing novel gene and cell therapies, alongside vaccines, to address a range of significant health challenges. The company's innovative pipeline emphasizes its modifier gene therapy platform, which employs a gene-agnostic strategy designed to potentially treat numerous retinal diseases with a single therapeutic agent. Leading their ocular initiatives, OCU400 is currently undergoing Phase 3 clinical trials for inherited retinal dystrophies like Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA), with plans for Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions anticipated by mid-2026. Another key program, OCU410ST, a modifier gene therapy for Stargardt disease, recently commenced its Phase 2/3 pivotal confirmatory trial, targeting a BLA filing in 2027. Additionally, OCU410, aimed at geographic atrophy secondary to dry age-related macular degeneration (dAMD), completed Phase 2 dosing and is slated for Phase 3 in 2026. Beyond gene therapies, Ocugen is progressing OCU200, a recombinant fusion protein, now in Phase 1 for conditions such as diabetic macular edema (DME), diabetic retinopathy, and wet AMD. The company is also involved in vaccine development, including an inhaled COVID-19 vaccine (OCU500) within a NIAID-funded trial, and has a cell therapy, NeoCart, in Phase 3 for knee cartilage repair. Ocugen engages in strategic alliances to propel its development and commercialization efforts. It maintains a collaboration with CanSino Biologics Inc. for the co-development and manufacturing of its gene therapy candidates, which includes commercialization rights in Greater China. The company also recently entered a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400, providing upfront and milestone payments, as well as royalties. Furthermore, Ocugen continues its partnership with Bharat Biotech for the commercialization of COVAXIN in the United States. The company is headquartered in Malvern, Pennsylvania.

Company News

  • Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy

  • Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN

  • Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises

  • Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript

  • Ocugen Q3 Earnings Call Highlights

  • Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates

  • Ocugen Provides Business Update with Third Quarter 2026 Financial Results

  • Ocugen to Participate in Upcoming November Investor and Industry Conferences

  • Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

  • Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

  • Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

  • Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

  • Ocugen to Participate in Upcoming Scientific Conferences

  • Ocugen to Participate in Upcoming October Investor and Industry Conferences

  • Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

  • Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

  • Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical

  • OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

  • Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration